US20120004452A1 - Intermediate compounds and their use in preparation of lacosamide - Google Patents
Intermediate compounds and their use in preparation of lacosamide Download PDFInfo
- Publication number
- US20120004452A1 US20120004452A1 US13/154,807 US201113154807A US2012004452A1 US 20120004452 A1 US20120004452 A1 US 20120004452A1 US 201113154807 A US201113154807 A US 201113154807A US 2012004452 A1 US2012004452 A1 US 2012004452A1
- Authority
- US
- United States
- Prior art keywords
- minutes
- compound
- formula
- added
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 title claims abstract description 61
- 229960002623 lacosamide Drugs 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 150000001875 compounds Chemical class 0.000 title abstract description 83
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 abstract description 37
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 110
- 239000000243 solution Substances 0.000 description 84
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000010410 layer Substances 0.000 description 37
- 239000000203 mixture Substances 0.000 description 32
- 239000002904 solvent Substances 0.000 description 30
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 24
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000002585 base Substances 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical group NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000007069 methylation reaction Methods 0.000 description 15
- -1 amino, hydroxy Chemical group 0.000 description 14
- 239000003960 organic solvent Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- HZEFRMKXCIOSOX-MUUNZHRXSA-N (2r)-n-benzyl-3-methoxy-2-(tritylamino)propanamide Chemical compound N([C@H](COC)C(=O)NCC=1C=CC=CC=1)C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 HZEFRMKXCIOSOX-MUUNZHRXSA-N 0.000 description 11
- CAXCRXDCRBCENL-HXUWFJFHSA-N (2r)-3-hydroxy-2-(tritylazaniumyl)propanoate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](CO)C(O)=O)C1=CC=CC=C1 CAXCRXDCRBCENL-HXUWFJFHSA-N 0.000 description 10
- WPLANNRKFDHEKD-SNVBAGLBSA-N Descarbonyl-lacosamide Chemical compound COC[C@@H](N)C(=O)NCC1=CC=CC=C1 WPLANNRKFDHEKD-SNVBAGLBSA-N 0.000 description 10
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 0 [1*]CC(NC)C([2*])=O.[1*]C[C@@H](NC)C([2*])=O.[1*]C[C@H](NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C([2*])=O Chemical compound [1*]CC(NC)C([2*])=O.[1*]C[C@@H](NC)C([2*])=O.[1*]C[C@H](NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C([2*])=O 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 238000005866 tritylation reaction Methods 0.000 description 9
- GXSNWOFNEBLUOB-HHHXNRCGSA-N (2r)-n-benzyl-3-hydroxy-2-(tritylamino)propanamide Chemical compound N([C@H](CO)C(=O)NCC=1C=CC=CC=1)C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 GXSNWOFNEBLUOB-HHHXNRCGSA-N 0.000 description 8
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000006640 acetylation reaction Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000012265 solid product Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000021736 acetylation Effects 0.000 description 6
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000012454 non-polar solvent Substances 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- MISORHVNJUJQLZ-OAQYLSRUSA-N (2r)-3-methoxy-2-(tritylamino)propanoic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N[C@H](COC)C(O)=O)C1=CC=CC=C1 MISORHVNJUJQLZ-OAQYLSRUSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 5
- 229930195711 D-Serine Natural products 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 239000012022 methylating agents Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000006340 racemization Effects 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- VPPJLAIAVCUEMN-UHFFFAOYSA-N 2-acetamido-n-benzyl-3-methoxypropanamide Chemical compound COCC(NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- PAOCVGPSHDDPRT-MUUNZHRXSA-N CC[C@@H](NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)NCC1=CC=CC=C1 Chemical compound CC[C@@H](NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)NCC1=CC=CC=C1 PAOCVGPSHDDPRT-MUUNZHRXSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- PBFYKXNLPYNWNL-SNVBAGLBSA-N CC[C@@H](N)C(=O)NCC1=CC=CC=C1 Chemical compound CC[C@@H](N)C(=O)NCC1=CC=CC=C1 PBFYKXNLPYNWNL-SNVBAGLBSA-N 0.000 description 3
- PEZVQCCHWXCHOV-GFCCVEGCSA-N CC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 Chemical compound CC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 PEZVQCCHWXCHOV-GFCCVEGCSA-N 0.000 description 3
- OMDUFRKEQKCGCU-OAQYLSRUSA-N CC[C@@H](NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)O Chemical compound CC[C@@H](NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)O OMDUFRKEQKCGCU-OAQYLSRUSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000012345 acetylating agent Substances 0.000 description 3
- 230000000397 acetylating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000007514 bases Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003495 polar organic solvent Substances 0.000 description 3
- 235000011118 potassium hydroxide Nutrition 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 2
- 239000003849 aromatic solvent Substances 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- FHLXUWOHGKLDNF-UHFFFAOYSA-N (2-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=CC=C1OC(Cl)=O FHLXUWOHGKLDNF-UHFFFAOYSA-N 0.000 description 1
- VPPJLAIAVCUEMN-LBPRGKRZSA-N (2s)-2-acetamido-n-benzyl-3-methoxypropanamide Chemical compound COC[C@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-LBPRGKRZSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- PBFYKXNLPYNWNL-UHFFFAOYSA-N CCC(N)C(=O)NCC1=CC=CC=C1 Chemical compound CCC(N)C(=O)NCC1=CC=CC=C1 PBFYKXNLPYNWNL-UHFFFAOYSA-N 0.000 description 1
- PEZVQCCHWXCHOV-UHFFFAOYSA-N CCC(NC(C)=O)C(=O)NCC1=CC=CC=C1 Chemical compound CCC(NC(C)=O)C(=O)NCC1=CC=CC=C1 PEZVQCCHWXCHOV-UHFFFAOYSA-N 0.000 description 1
- PAOCVGPSHDDPRT-UHFFFAOYSA-N CCC(NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)NCC1=CC=CC=C1 Chemical compound CCC(NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)NCC1=CC=CC=C1 PAOCVGPSHDDPRT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000008550 L-serines Chemical class 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- VSFYIPJGGXNVQM-UHFFFAOYSA-M azanium sodium hydrogen carbonate Chemical compound [NH4+].[Na+].OC([O-])=O.OC([O-])=O VSFYIPJGGXNVQM-UHFFFAOYSA-M 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to intermediate compounds and their use in preparation of lacosamide.
- Lacosamide (SPM 927, also referred to as harkoseride or ADD 234037), is chemically (R)-2-acetamido-N-benzyl-3-methoxypropionamide of Formula Ia. It shows effects in the treatment of pain, epilepsy, fibromyalgia syndrome, osteoarthritis and migraine. It is also known to be useful for the treatment of CNS disorders in humans.
- Lacosamide and its methods of preparation are disclosed in U.S. Reissue Pat. No. RE 38,551 (hereinafter referred to as the '551 patent).
- This reference provides three general methods for the preparation of lacosamide. The first two methods do not involve the protection of active groups in intermediate compounds (such as amino, hydroxy and carboxylic acid groups).
- the other method disclosed in the '551 patent involves protection of an amino group present in D-serine with carbobenzoxy chloride (Cbz-Cl), subsequent O-methylation at the hydroxy group followed by benzylamination at carboxylic (—COOH) group and finally removal of the ‘Cbz’ group followed by acetylation produces lacosamide.
- a new method for the preparation of lacosamide that gives excellent chiral purity and yield at low cost involves the use of particular intermediate compounds.
- the intermediate compounds of the present invention comprise bulky protecting groups that are capable of minimizing nucleophilic attack at chiral carbon atom, which is otherwise responsible for racemization, providing the chirally pure lacosamide in high yield.
- the present invention makes use of a bulkier group than “Boc” and “Cbz” during the present invention.
- novel intermediate compounds and use thereof for the preparation of lacosamide are aspects of the present invention.
- R 1 is —OH or —OMe
- R 2 is —OH or —NH—CH 2 —C 6 H 5 and the
- the compound of Formula II is useful pharmaceutical intermediate for the preparation of lacosamide.
- the present invention also contemplates processes for the preparation of lacosamide employing the compound of Formula II as an intermediate.
- the present invention also provides lacosamide substantially free of (S)-2-acetamido-N-benzyl-3-methoxypropionamide.
- lacosamide refers to the R-enantiomeric form of 2-acetamido-N-benzyl-3-methoxypropionamide.
- O-methylation refers to attachment of a methyl group to the main chain of a given compound through an oxygen bridge.
- O-methylation is a process of converting an —OH group into an —OMe group in a given chemical compound.
- benzylamination refers to attaching an —NH—CH 2 —C 6 H 5 group in a given compound in such a way that the terminal —NH moiety can form an amide group.
- de-tritylation refers to removal of a trityl group from a given compound.
- acetylation refers to attachment of a —COMe group to the N 2 -amino group of a given compound.
- N 2 -amino refers to the amino group located at the second position in the main carbon chain of a given compound.
- trityl refers to a triphenylmethyl group and “Me” refers to a methyl group.
- alkoxy refers to an —O-alkyl group, wherein the alkyl group has C 1 -C 6 carbon atoms such as methyl, ethyl, propyl, butyl, isobutyl, isopropyl, t-butyl, etc.
- R 1 is —OH or —OMe
- R 2 is —OH or —NH—CH 2 —C 6 H 5 and pharmaceutically acceptable salt, solvate, hydrate or enantiomeric form thereof.
- the compound of Formula II can exist independently as the R-enantiomer (Formula IIa), S-enantiomer (Formula IIb) or mixture.
- the R 1 and R 2 are —OH.
- the R 1 is —OH and R 2 is —NH—CH 2 —C 6 H 5 .
- the R 1 is —OMe and R 2 is —OH.
- the R 1 is —OMe and R 2 is —NH—CH 2 —C 6 H 5 .
- the compound of Formula II is N-trityl-D-serine; O-methyl-N-trityl-D-serine; N-benzyl-O-methyl-N 2 -trityl-D-serinamide or N-benzyl-N 2 -trityl-D-serinamide.
- the compound disclosed herein should be substantially pure, i.e., substantially free from impurities.
- the compound can be about 85% pure (w/w), or, for example, greater than about 90% pure (w/w), or, for example, than about 99% pure (w/w).
- the compounds presented herein can be enantiomerically pure, e.g., at least about 98% enantiomerically pure.
- One enantiomer substantially free of other enantiomer can be prepared.
- One enantiomer having no detectable amount of other enantiomer is another aspect of this disclosure.
- the present aspect also contemplates use of compound of Formula II, Formula IIa or Formula IIb for the preparation of lacosamide.
- the O-methylation step a) is performed by means of a methylating agent.
- Methylating agents such as methyl iodide, dimethyl sulfate, trimethyl silyldiazomethane, dimethyl sulfoxide (DMSO), for example, can be used for this purpose.
- DMSO dimethyl sulfoxide
- the O-methylation can be performed, under, for example, Williamson conditions by treating the compound of Formula III with QX, wherein Q is alkoxy and X is a leaving group, such as, for example, the tosyl (p-toluenesulfonyl) mesyl (methanesulfonyl) group.
- the O-methylation can also be performed either by using an organometailic compound with the methylating agent or by a phase-transfer reaction, for example, as described in PCT application WO 2006/37574.
- the O-methylation is generally performed in the presence of a base.
- the base can be, for example, hydride, hydroxide and/or oxides of metals, for example, hydride, hydroxide and/or oxides of sodium, potassium, calcium, silver, etc. can be used as base.
- the O-methylation can optionally be performed in the presence of a catalyst.
- Compounds including for example, imidazole, dimethylaminopyridine (DMAP), pyridine etc. can be used as catalysts in the reaction.
- the solvents that can be used for the O-methylation reaction are generally organic solvents.
- organic solvents e.g., tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), acetonitrile (MeCN) etc. can be used.
- a solution of compound of Formula in polar organic solvent is mixed with a solution containing base, catalyst and polar organic solvent.
- the methylating agent is then added to this mixture.
- the reaction is usually allowed to proceed for at least 2 hours at ⁇ 20 to 0° C., and preferably for 2.5-5 hours at ⁇ 18° C. to ⁇ 3° C., most preferably for 3-4 hours at ⁇ 15° C. to ⁇ 5° C. Also, the reaction may be performed at higher or lower temperatures such as any temperature between ⁇ 20° C. and 0° C. if the reaction time is adapted accordingly.
- the O-methylated compound of Formula IV is then isolated from the mixture and purified with non-polar solvent.
- Methyl iodide can be used as the methylating agent, sodium hydride or potassium hydroxide as the base, imidazole as the catalyst and THF or DMSO as the solvent for the O-methylation purpose.
- Non-polar solvent may be used for the purification of the O-methylated compound of Formula IV.
- non-polar solvents e.g., hexane, heptane, ethers, like petroleum ether, diethyl ether, di-isopropyl ether etc. can be used for the purification purpose.
- the O-methylated compound of Formula IV can be optionally subjected to a benzylamination reaction (step-b).
- the benzylaminating agent used for this purpose is benzylamine (C 6 H 5 CH 2 NH 2 ).
- the carbonyl moiety present in the compound of Formula IV forms an amide group with the —NH 2 moiety of benzylamine in this reaction.
- the reaction can be performed with benzylamine optionally in a mixed-anhydride condition.
- the mixed-anhydride coupling reaction conditions are described by, for example, Anderson, et, at. JACS (1967), 89, 5012-5017, the contents of which are incorporated herein by reference.
- the carbonyl group present in Formula IV needs activation before the benzylamination reaction.
- Some of the examples of compounds that can act as an activator of the carbonyl group are optionally substituted alkyl or aryl chloroformates such as methyl chloroformate, isobutyl chloroformate (IBCF), phenyl chloroformate, nitro-phenyl chloroformate, etc.; azoles such as 1-hydroxybenzotriazole (HOBT) and the like; or imides such as 1,3-dicyclohexylcarbodi-imide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodi-imide (EDC) and the like.
- DCC 1,3-dicyclohexylcarbodi-imide
- EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodi-imide
- the benzylamination reaction can be performed in presence of a base.
- the base selected for the purpose is generally a nitrogen-containing base.
- suitable bases are morpholine, N-methyl morpholine (NMM), triethylamine, diethylamine, isopropylamine (IPA) etc.
- the solvent used for benzylamination reaction can be an organic solvent.
- the organic solvent can be, for example, an aliphatic, alicyclic or aromatic solvent.
- Some examples of solvent are dichloromethane, trichloromethane, tetrachloromethane, ethyl acetate, toluene, tetrahydrofuran (THF), oxirane, acetone and the like.
- the base and solution of the activator compound in organic solvent are mixed with a solution of compound of Formula in organic solvent, sequentially.
- the benzylaminating agent is then added to the mixture.
- the reaction is usually allowed to proceed for at least 1 hour at ⁇ 20° C. to 40° C. and preferably for 1.5 hours at ⁇ 18° C. to 35° C., most preferably for 2-3 hours at ⁇ 15° C. to 30° C. Also, the reaction may be performed at higher or tower temperatures such as any temperature between ⁇ 20° C. and 40° C. if the reaction time is adapted accordingly.
- the benzylaminated compound of Formula V is then isolated and/or purified with non-polar solvent.
- benzylamine as benzylaminating agent, isobutyl chloroformate (IBCF) as an activator of carbonyl group, N-methyl morpholine (NMM) as base and tetrahydrofuran (THF) or ethyl acetate as solvent are used for the benzylamination.
- Non-polar solvents may be used for the isolation/purification of benzylaminated compound of Formula V.
- Non-polar solvents such as hexane, heptane, ether like petroleum ether, diethyl ether, di-isopropyl ether etc, can be used for the isolation/purification.
- the O-methylated and benzylaminated compound of Formula V is then subjected to de-tritylation reaction (step-c).
- the de-tritylation can be performed using de-tritylating agents like acids. Strong as well as mild acidic conditions can be suitable for the de-tritylation reaction. Mild acids e.g., acetic acid, etc. or strong acids e.g., hydrochloric acid, sulphuric acid, trifluoroacetic acid, etc, can be used. Organic solvents (aromatic or aliphatic) can be used during the reaction.
- Aromatic solvents e.g., toluene, xylene etc., and aliphatic solvents like chlorinated solvents e.g., dichloromethane, chloroform etc.; alcohols e.g., methanol, ethanol, isopropanol, etc. can be used for the de-tritylation purpose.
- Basic compounds can be used to neutralize the reaction medium. A solution of strong or mild basic compounds is suitable for neutralization.
- Some examples of these basic compounds are ammonia, ammonium hydroxide, ammonium carbonate, ammonium bicarbonate sodium bicarbonate, sodium carbonate, sodium hydroxide, potassium bicarbonate, potassium carbonate, potassium hydroxide, calcium bicarbonate, calcium hydroxide, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium bicarbonate, etc.
- the acid is added to the solution of compound of Formula V in organic solvent and the de-tritylation reaction is allowed to proceed for about 1 hour at 15° C. to 40° C., preferably for 20-50 minutes at 20° C. to 35° C., most preferably for 30-40 minutes at 25° C. to 30° C.
- the reaction may be performed at higher or lower temperatures such as any temperature between 15° C. and 40° C. if the reaction time is adapted accordingly.
- a solution of the base compound is added to the reaction mixture.
- the de-tritylated compound of Formula VI is then isolated from the reaction mixture and optionally purified.
- Hydrochloric acid or acetic acid as de-tritylating agent, dichloromethane or ethanol as organic solvent and aqueous ammonia solution as base can be used for neutralization.
- the de-tritylated compound of Formula VI is isolated and optionally purified using organic solvents e.g., dichloromethane, toluene, ethanol, etc.
- the de-tritylated compound of Formula VI can be acetylated to produce the compound of Formula I (step-d).
- acetic anhydride, acetyl chloride, acetic acid or the like and derivatives thereof may be used as an acetylating agent.
- the acetylation can be performed in the presence or absence of a base.
- the base can be a nitrogen-containing base e.g., pyridine, dimethylaminopyridine, etc.
- the acetylation reaction can be performed in presence of organic solvents e.g., dichloromethane, toluene, ethyl acetate, etc.
- Acetic anhydride as acetylating agent, dichloromethane or ethyl acetate as organic solvent and dimethylaminopyridine as base can be used for the acetylation.
- the compound of Formula I, so formed, is purified with the help of suitable organic solvents such as dichloromethane, toluene, ethanol, ethyl acetate, etc.
- the compound of Formula III of present aspect can be prepared by reacting the corresponding serine compound with trityl chloride.
- the hydroxy and/or carboxylic group of the corresponding serine compound can be protected by a silyl protecting group like, for example, trimethylsilyl, hexamethyldisilazane, etc. and then the free amino group in the compound can be selectively tritylated. Subsequently, the silyl protecting group can be removed by hydrolysis reaction, providing high yields of the compound of Formula III.
- a racemic serine compound may be utilized as the starting material. Following the procedure outlined herein would provide the racemic mixture, which can be resolved into the R or S enantiomer by standard techniques known in the art.
- the process outlined herein starting from serine compound in its racemic, R or S enantiomeric form provides the final compound of Formula I in corresponding racemic, R or S form, respectively.
- the optical purity of the product may be enhanced by further separation of the S-enantiomer from the R-enantiomer, by standard techniques known in the art.
- D-serine (i.e., R-enantiomer) derivatives or L-serine (i.e., S-enantiomer) derivatives or mixtures of D- and L-serine derivatives in any ratio may be used in the method of the present aspect.
- a third aspect of the present invention provides a process for the preparation of lacosamide comprising:
- R 2 is —OH or —NH—CH 2 —C 6 H 5 .
- racemization is avoided during the process of the present aspect.
- the lacosamide obtained by following the process of this aspect is substantially chirally pure.
- the substantial chiral purity refers to the purity in which no detectable amount of corresponding S-enantiomer is present in lacosamide.
- lacosamide prepared by following the process of this aspect is substantially free of impurities.
- Lacosamide having at least about 99% purity, preferably at least about 99.8% purity and most preferably at least about 99.9% purity can be obtained by the process of present aspect.
- a process for the preparation of lacosamide comprising the steps of:
- racemization is avoided during the process of the present aspect.
- the lacosamide obtained by following the process of this aspect is substantially chirally pure.
- the substantial chiral purity refers to the purity in which no detectable amount of corresponding S-enantiomer is present in lacosamide.
- lacosamide prepared by following the process of this aspect is substantially free of impurities.
- Lacosamide having at least about 99% purity, preferably at least about 99.8% purity and most preferably at least about 99.9% purity can be obtained by the process of present aspect.
- a process for the preparation of lacosamide comprising the steps of:
- racemization is avoided during the process.
- the lacosamide obtained by following the process of this aspect is substantially chirally pure.
- the substantial chiral purity refers to the purity in which no detectable amount of corresponding S-enantiomer is present in lacosamide.
- lacosamide prepared by following the process of this aspect is substantially free of impurities.
- Lacosamide having at least about 99% purity, preferably at least about 99.8% purity and most preferably at least about 99.9% purity can be obtained by the process of present aspect.
- substantially chirally pure lacosamide is provided.
- lacosamide having chiral purity of more than about 99.8% is preferred. More preferably, lacosamide having chiral purity of at least about 99.9% and most preferably lacosamide having no detectable amount of corresponding S-enantiomer (i.e., 100% chiral purity) is an object of this aspect.
- composition comprising a pharmaceutically effective amount of substantially chirally pure lacosamide along with pharmaceutically acceptable carrier, diluent and/or excipient is provided.
- the filtered product was further washed with 5% citric acid solution (750 ml) and filtered.
- the solid product obtained was partitioned between water (750 ml) and hexanes (200 ml) and then filtered.
- Example 1 product i.e., N-trityl-D-serine, 50 g
- Methyl iodide 40.8 g was added to the mixture in 15 minutes at ⁇ 15° C. to ⁇ 5° C. and the reaction mixture was stirred at ⁇ 5° C. for 3 hours.
- Example 2 product i.e., O-methyl-N-trityl-D-serine, 50 g
- N-methyl morpholine 20.9 g
- isobutylchloroformate 18.8 g
- benzyl amine (14.7 g) was added to it at ⁇ 0.15° C. in 15 minutes.
- the solution was allowed to cool to room temperature and stirred for 2 hours. The solvent was recovered from the solution.
- Example 2 product i.e., O-methyl-N-trityl-D-serine, 50 g
- N-methyl morpholine 20.9 g
- the reaction mixture was stirred for 15 minutes and then isobutylchloroformate (18.8 g) already diluted with tetrahydrofuran was added to it at ⁇ 15° C. under nitrogen atmosphere in 15-20 minutes.
- the solution was stirred for 15 minutes and benzyl amine (14.7 g) was added to it at ⁇ 15° C. in 15 minutes.
- the solution was allowed to cool to room temperature and stirred for 2 hours.
- the solvent was recovered from the solution.
- Example 3 product i.e. N-benzyl-O-methyl-N 2 -trityl-D-serinamide, 50 g
- dichloromethane 100 ml
- hydrochloric acid 36%) was added at room temperature. This solution was stirred for 30 minutes at room temperature and then the solvent was completely recovered under vacuum at 40° C.
- Example 3 product i.e., N-benzyl-O-methyl-N 2 -trityl-D-serinamide, 50 g
- absolute ethanol 100 ml
- acetic acid 1.25 mole eq.
- Water 250 ml was added to it at room temperature and the aqueous layer was neutralized with aqueous ammonia (20 ml).
- N-trityl-D-serine 50 g
- tetrahydrofuran 500 ml
- N-methyl morpholine 15.72 g
- isobutylchloroformate 20.84 g
- benzyl amine 18.51 g
- the solution was allowed to cool to room temperature and stirred for 2 hours.
- the solvent was recovered from the solution.
- Dichloromethane (250 ml) was added to the crude product and stirred for 5 minutes to dissolve.
- the dichloromethane layer was washed or stirred for 5 minutes with water (250 ml).
- the layers were separated and the dichloromethane layer was again washed with 5% NaHCO 3 (250 ml).
- the layers were separated and then the dichloromethane layer was sequentially washed with 5% citric acid solution (250 ml) and then with water (250 ml).
- the solvent was recovered at 40° C. to 45° C. to get oil.
- N-trityl-D-serine 50 g
- ethyl acetate 500 ml
- N-methyl morpholine 15.72 g
- isobutylchloroformate 20.84 g
- benzyl amine 18.51 g
- the solution was allowed to cool to room temperature and stirred for 2 hours.
- the solvent was recovered from the solution.
- Dichloromethane (250 ml) was added to the crude product and stirred for 5 minutes to dissolve.
- the dichloromethane layer was washed or stirred for 5 minutes with water (250 ml).
- the layers were separated and the dichloromethane layer was again washed with 5% NaHCO3 (250 ml).
- the layers were separated and then the dichloromethane layer was sequentially washed with 5% citric acid solution (250 ml) and then with water (250 ml).
- the solvent was recovered at 40° C. to 45° C. to get oil.
- Example 5 product i.e. N-benzyl-N 2 -trityl-D-serinamide, 50 g
- tetrahydrofuran 500 ml
- Methyl iodide 24.38 g was slowly added to the mixture for 15 minutes at ⁇ 15° C. to ⁇ 5° C. and the formed reaction mixture was stirred at ⁇ 5° C. for 3 hours.
- the reaction mixture was cooled to 0° C.
- Example 5 product i.e., N-benzyl-N 2 -trityl-D-serinamide, 2 g
- Methyl iodide (0.97 g) was slowly added to the mixture for 15 minutes at ambient temperature and stirred for 30 minutes.
- N-benzyl-O-methyl-D-serinamide 50 g
- dichloromethane 500 ml
- dichloromethane 500 ml
- dimethylaminopyridine 1.04 g
- acetic anhydride 24.48 g
- the solution was stirred for 10 minutes at 10° to 5° C. and raised to room temperature (25°-30° C.) in over 30 minutes.
- the solution was further stirred for 30 minutes at room temperature.
- the reaction mixture was washed with 8% sodium bicarbonate (250 ml) solution.
- N-benzyl-O-methyl-D-serinamide 50 g
- ethyl acetate 500 ml
- dimethylaminopyridine 1.04 g
- acetic anhydride 24.48 g
- the solution was stirred for 10 minutes at 10° to 5° C. and raised to room temperature (25° to 30° C.) in over 30 minutes.
- the solution was further stirred for 30 minutes at room temperature.
- N-benzyl-O-methyl-D-serinamide 50 g
- dichloromethane 500 ml
- dichloromethane 500 ml
- dimethylaminopyridine 1.04 g
- acetic anhydride 24.48 g
- the solution was stirred for 10 minutes at 10° to 5° C. and raised to room temperature (25°-30° C.) in over 30 minutes.
- the solution was further stirred for 30 minutes at room temperature.
- the reaction mixture was washed with 8% sodium bicarbonate (250 ml) solution.
- N-benzyl-O-methyl-D-serinamide 50 g
- ethyl acetate 500 ml
- dimethylaminopyridine 1.04 g
- acetic anhydride 24.48 g
- the solution was stirred for 10 minutes at 10° to 5° C. and raised to room temperature (25° to 30° C.) in over 30 minutes.
- the solution was further stirred for 30 minutes at room temperature.
- N-benzyl-O-methyl-D-serinamide (92 g), was mixed with dichloromethane (368 ml) at ambient temperature and stirred for 10 minutes to get a clear solution.
- dichloromethane 368 ml
- dimethylaminopyridine (0.47 g) was added at ambient temperature.
- Acetic anhydride 45.09 g was slowly added over 15-20 minutes at ambient temperature.
- the solution was stirred for 2 hours at room temperature.
- N-benzyl-O-methyl-D-serinamide (5 g), was mixed with DCM (25 ml) at ambient temperature and stirred for 10 minutes to get a clear solution.
- dimethylaminopyridine (0.025 g) was added at ambient temperature.
- Acetic anhydride (2.695 g) was slowly added over 10-12 minutes at ambient temperature.
- the solution was stirred for 30 minutes at room temperature.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is concerned with novel compounds and their use for the preparation of lacosamide. The present invention also contemplates processes for the preparation of lacosamide employing the novel compound of general Formula II, Formula IIa or Formula IIb as intermediate.
Wherein
-
- R1 is —OH or —OMe;
- R2 is —OH or —NH—CH2—C6H5.
Description
- This application is a divisional application of U.S. patent application Ser. No. 12/327,124 filed on Dec. 3, 2008, the contents of which are incorporated herein in its entirety.
- The present invention relates to intermediate compounds and their use in preparation of lacosamide.
- Lacosamide (SPM 927, also referred to as harkoseride or ADD 234037), is chemically (R)-2-acetamido-N-benzyl-3-methoxypropionamide of Formula Ia. It shows effects in the treatment of pain, epilepsy, fibromyalgia syndrome, osteoarthritis and migraine. It is also known to be useful for the treatment of CNS disorders in humans.
- Lacosamide and its methods of preparation are disclosed in U.S. Reissue Pat. No. RE 38,551 (hereinafter referred to as the '551 patent). This reference provides three general methods for the preparation of lacosamide. The first two methods do not involve the protection of active groups in intermediate compounds (such as amino, hydroxy and carboxylic acid groups). The other method disclosed in the '551 patent involves protection of an amino group present in D-serine with carbobenzoxy chloride (Cbz-Cl), subsequent O-methylation at the hydroxy group followed by benzylamination at carboxylic (—COOH) group and finally removal of the ‘Cbz’ group followed by acetylation produces lacosamide.
- An alternative method for the preparation of lacosamide is disclosed in PCT publication WO 2006/037574 (hereinafter referred to as '574 application) that involves O-methylation of N-Boc-protected-D-serine (“Boc” refers to t-butoxycarbonyl) directly in one step by avoiding simultaneous formation of the methyl ester moiety.
- In view of the preparation methods available for lacosamide, there is a need for simple and cost effective processes for the preparation of lacosamide that eliminates racemization of intermediate compounds and final product and provides improved efficiency per reaction volume in terms of yield, purity and chiral purity.
- A new method for the preparation of lacosamide that gives excellent chiral purity and yield at low cost is provided. The new method involves the use of particular intermediate compounds. The intermediate compounds of the present invention comprise bulky protecting groups that are capable of minimizing nucleophilic attack at chiral carbon atom, which is otherwise responsible for racemization, providing the chirally pure lacosamide in high yield. The present invention makes use of a bulkier group than “Boc” and “Cbz” during the present invention.
- Thus, the novel intermediate compounds and use thereof for the preparation of lacosamide are aspects of the present invention.
- Accordingly, the present invention is directed to compound of Formula II
- wherein
- R1 is —OH or —OMe;
- R2 is —OH or —NH—CH2—C6H5 and the
- pharmaceutically acceptable salts, solvates, hydrates or enantiomeric forms thereof.
- The compound of Formula II is useful pharmaceutical intermediate for the preparation of lacosamide.
- The present invention also contemplates processes for the preparation of lacosamide employing the compound of Formula II as an intermediate.
- The present invention also provides lacosamide substantially free of (S)-2-acetamido-N-benzyl-3-methoxypropionamide.
- The term “lacosamide” as used herein refers to the R-enantiomeric form of 2-acetamido-N-benzyl-3-methoxypropionamide.
- The term “O-methylation” as used herein refers to attachment of a methyl group to the main chain of a given compound through an oxygen bridge. Alternatively the “O-methylation” is a process of converting an —OH group into an —OMe group in a given chemical compound. The term “benzylamination” as used herein refers to attaching an —NH—CH2—C6H5 group in a given compound in such a way that the terminal —NH moiety can form an amide group. The term “de-tritylation” as used herein refers to removal of a trityl group from a given compound. The term “acetylation” as used herein refers to attachment of a —COMe group to the N2-amino group of a given compound. The term “N2-amino” refers to the amino group located at the second position in the main carbon chain of a given compound. The term “trityl” as used herein refers to a triphenylmethyl group and “Me” refers to a methyl group.
- The term “alkoxy” as used herein refers to an —O-alkyl group, wherein the alkyl group has C1-C6 carbon atoms such as methyl, ethyl, propyl, butyl, isobutyl, isopropyl, t-butyl, etc.
- In a first aspect, a compound of the general Formula II is provided,
- wherein R1 is —OH or —OMe; and R2 is —OH or —NH—CH2—C6H5 and pharmaceutically acceptable salt, solvate, hydrate or enantiomeric form thereof.
- In an embodiment of this aspect, the compound of Formula II can exist independently as the R-enantiomer (Formula IIa), S-enantiomer (Formula IIb) or mixture.
- In another embodiment of the present aspect, the R1 and R2 are —OH.
- In another embodiment of the present aspect, the R1 is —OH and R2 is —NH—CH2—C6H5.
- In another embodiment of the present aspect, the R1 is —OMe and R2 is —OH.
- In another embodiment of the present aspect, the R1 is —OMe and R2 is —NH—CH2—C6H5.
- In another embodiment of the present aspect, the compound of Formula II is N-trityl-D-serine; O-methyl-N-trityl-D-serine; N-benzyl-O-methyl-N2-trityl-D-serinamide or N-benzyl-N2-trityl-D-serinamide.
- The compound disclosed herein should be substantially pure, i.e., substantially free from impurities. For example, the compound can be about 85% pure (w/w), or, for example, greater than about 90% pure (w/w), or, for example, than about 99% pure (w/w).
- In another embodiment of this aspect, the compounds presented herein can be enantiomerically pure, e.g., at least about 98% enantiomerically pure. One enantiomer substantially free of other enantiomer can be prepared. One enantiomer having no detectable amount of other enantiomer is another aspect of this disclosure.
- The present aspect also contemplates use of compound of Formula II, Formula IIa or Formula IIb for the preparation of lacosamide.
- In a second aspect, a process for the preparation of 2-acetamido-N-benzyl-3-methoxypropionamide of Formula I is provided.
- comprising the steps of:
-
- a) O-methylating the compound of Formula III
-
-
- to produce a compound of Formula IV
-
-
-
- wherein R2 is —OH or —NH—CH2—C6H5;
- b) optionally benzylaminating the compound of Formula IV to produce a compound of Formula V;
-
-
- c) de-tritylating the compound of Formula V to produce the compound of Formula VI;
- d) acetylating the compound of Formula VI to produce the compound of Formula I.
- In an embodiment of this aspect, the O-methylation step a) is performed by means of a methylating agent. Methylating agents such as methyl iodide, dimethyl sulfate, trimethyl silyldiazomethane, dimethyl sulfoxide (DMSO), for example, can be used for this purpose. The O-methylation can be performed, under, for example, Williamson conditions by treating the compound of Formula III with QX, wherein Q is alkoxy and X is a leaving group, such as, for example, the tosyl (p-toluenesulfonyl) mesyl (methanesulfonyl) group. The O-methylation can also be performed either by using an organometailic compound with the methylating agent or by a phase-transfer reaction, for example, as described in PCT application WO 2006/37574. The O-methylation is generally performed in the presence of a base. The base can be, for example, hydride, hydroxide and/or oxides of metals, for example, hydride, hydroxide and/or oxides of sodium, potassium, calcium, silver, etc. can be used as base. The O-methylation can optionally be performed in the presence of a catalyst. Compounds including for example, imidazole, dimethylaminopyridine (DMAP), pyridine etc. can be used as catalysts in the reaction. The solvents that can be used for the O-methylation reaction are generally organic solvents. For example, polar organic solvents, e.g., tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), acetonitrile (MeCN) etc. can be used.
- Accordingly, a solution of compound of Formula in polar organic solvent is mixed with a solution containing base, catalyst and polar organic solvent. The methylating agent is then added to this mixture. The reaction is usually allowed to proceed for at least 2 hours at −20 to 0° C., and preferably for 2.5-5 hours at −18° C. to −3° C., most preferably for 3-4 hours at −15° C. to −5° C. Also, the reaction may be performed at higher or lower temperatures such as any temperature between −20° C. and 0° C. if the reaction time is adapted accordingly. The O-methylated compound of Formula IV is then isolated from the mixture and purified with non-polar solvent.
- Methyl iodide can be used as the methylating agent, sodium hydride or potassium hydroxide as the base, imidazole as the catalyst and THF or DMSO as the solvent for the O-methylation purpose. Non-polar solvent may be used for the purification of the O-methylated compound of Formula IV. Preferably, non-polar solvents, e.g., hexane, heptane, ethers, like petroleum ether, diethyl ether, di-isopropyl ether etc. can be used for the purification purpose.
- In another embodiment of this aspect, the O-methylated compound of Formula IV can be optionally subjected to a benzylamination reaction (step-b). The benzylaminating agent used for this purpose is benzylamine (C6H5CH2NH2). The carbonyl moiety present in the compound of Formula IV forms an amide group with the —NH2 moiety of benzylamine in this reaction. The reaction can be performed with benzylamine optionally in a mixed-anhydride condition. The mixed-anhydride coupling reaction conditions are described by, for example, Anderson, et, at. JACS (1967), 89, 5012-5017, the contents of which are incorporated herein by reference. The carbonyl group present in Formula IV needs activation before the benzylamination reaction. Some of the examples of compounds that can act as an activator of the carbonyl group are optionally substituted alkyl or aryl chloroformates such as methyl chloroformate, isobutyl chloroformate (IBCF), phenyl chloroformate, nitro-phenyl chloroformate, etc.; azoles such as 1-hydroxybenzotriazole (HOBT) and the like; or imides such as 1,3-dicyclohexylcarbodi-imide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodi-imide (EDC) and the like. The benzylamination reaction can be performed in presence of a base. The base selected for the purpose is generally a nitrogen-containing base. Some examples of suitable bases are morpholine, N-methyl morpholine (NMM), triethylamine, diethylamine, isopropylamine (IPA) etc. The solvent used for benzylamination reaction can be an organic solvent. The organic solvent can be, for example, an aliphatic, alicyclic or aromatic solvent. Some examples of solvent are dichloromethane, trichloromethane, tetrachloromethane, ethyl acetate, toluene, tetrahydrofuran (THF), oxirane, acetone and the like.
- Accordingly, the base and solution of the activator compound in organic solvent are mixed with a solution of compound of Formula in organic solvent, sequentially. The benzylaminating agent is then added to the mixture. The reaction is usually allowed to proceed for at least 1 hour at −20° C. to 40° C. and preferably for 1.5 hours at −18° C. to 35° C., most preferably for 2-3 hours at −15° C. to 30° C. Also, the reaction may be performed at higher or tower temperatures such as any temperature between −20° C. and 40° C. if the reaction time is adapted accordingly. The benzylaminated compound of Formula V is then isolated and/or purified with non-polar solvent.
- Typically, benzylamine as benzylaminating agent, isobutyl chloroformate (IBCF) as an activator of carbonyl group, N-methyl morpholine (NMM) as base and tetrahydrofuran (THF) or ethyl acetate as solvent are used for the benzylamination. Non-polar solvents may be used for the isolation/purification of benzylaminated compound of Formula V. Non-polar solvents such as hexane, heptane, ether like petroleum ether, diethyl ether, di-isopropyl ether etc, can be used for the isolation/purification.
- In another embodiment of this aspect, the O-methylated and benzylaminated compound of Formula V is then subjected to de-tritylation reaction (step-c). The de-tritylation can be performed using de-tritylating agents like acids. Strong as well as mild acidic conditions can be suitable for the de-tritylation reaction. Mild acids e.g., acetic acid, etc. or strong acids e.g., hydrochloric acid, sulphuric acid, trifluoroacetic acid, etc, can be used. Organic solvents (aromatic or aliphatic) can be used during the reaction. Aromatic solvents e.g., toluene, xylene etc., and aliphatic solvents like chlorinated solvents e.g., dichloromethane, chloroform etc.; alcohols e.g., methanol, ethanol, isopropanol, etc. can be used for the de-tritylation purpose. Basic compounds can be used to neutralize the reaction medium. A solution of strong or mild basic compounds is suitable for neutralization. Some examples of these basic compounds are ammonia, ammonium hydroxide, ammonium carbonate, ammonium bicarbonate sodium bicarbonate, sodium carbonate, sodium hydroxide, potassium bicarbonate, potassium carbonate, potassium hydroxide, calcium bicarbonate, calcium hydroxide, calcium carbonate, magnesium hydroxide, magnesium carbonate, magnesium bicarbonate, etc.
- Accordingly, the acid is added to the solution of compound of Formula V in organic solvent and the de-tritylation reaction is allowed to proceed for about 1 hour at 15° C. to 40° C., preferably for 20-50 minutes at 20° C. to 35° C., most preferably for 30-40 minutes at 25° C. to 30° C. Also, the reaction may be performed at higher or lower temperatures such as any temperature between 15° C. and 40° C. if the reaction time is adapted accordingly. After completion of the reaction, a solution of the base compound is added to the reaction mixture. The de-tritylated compound of Formula VI is then isolated from the reaction mixture and optionally purified.
- Hydrochloric acid or acetic acid as de-tritylating agent, dichloromethane or ethanol as organic solvent and aqueous ammonia solution as base can be used for neutralization. The de-tritylated compound of Formula VI is isolated and optionally purified using organic solvents e.g., dichloromethane, toluene, ethanol, etc.
- In another embodiment of present aspect, the de-tritylated compound of Formula VI can be acetylated to produce the compound of Formula I (step-d). For this purpose, acetic anhydride, acetyl chloride, acetic acid or the like and derivatives thereof may be used as an acetylating agent. The acetylation can be performed in the presence or absence of a base. The base can be a nitrogen-containing base e.g., pyridine, dimethylaminopyridine, etc. The acetylation reaction can be performed in presence of organic solvents e.g., dichloromethane, toluene, ethyl acetate, etc.
- Accordingly, base is added to the solution of compound of Formula VI in organic solvent and acetylating agent is then slowly added to the mixture. The reaction is allowed to proceed for up to 2 hours at temperature ranging from 5° C. to 40° C. The compound of Formula I is then isolated from the reaction mixture and purified.
- Acetic anhydride as acetylating agent, dichloromethane or ethyl acetate as organic solvent and dimethylaminopyridine as base can be used for the acetylation. The compound of Formula I, so formed, is purified with the help of suitable organic solvents such as dichloromethane, toluene, ethanol, ethyl acetate, etc.
- The compound of Formula III of present aspect can be prepared by reacting the corresponding serine compound with trityl chloride. The hydroxy and/or carboxylic group of the corresponding serine compound can be protected by a silyl protecting group like, for example, trimethylsilyl, hexamethyldisilazane, etc. and then the free amino group in the compound can be selectively tritylated. Subsequently, the silyl protecting group can be removed by hydrolysis reaction, providing high yields of the compound of Formula III.
- In another embodiment of present aspect, a racemic serine compound may be utilized as the starting material. Following the procedure outlined herein would provide the racemic mixture, which can be resolved into the R or S enantiomer by standard techniques known in the art.
- In a further embodiment of present aspect, the process outlined herein starting from serine compound in its racemic, R or S enantiomeric form provides the final compound of Formula I in corresponding racemic, R or S form, respectively. If necessary, the optical purity of the product may be enhanced by further separation of the S-enantiomer from the R-enantiomer, by standard techniques known in the art. D-serine (i.e., R-enantiomer) derivatives or L-serine (i.e., S-enantiomer) derivatives or mixtures of D- and L-serine derivatives in any ratio may be used in the method of the present aspect.
- A third aspect of the present invention provides a process for the preparation of lacosamide comprising:
- O-methylating the compound of Formula IIIa
- to produce the compound of Formula IVa
- wherein R2 is —OH or —NH—CH2—C6H5.
- The O-methylation method, reagents (methylating agent, base, catalyst, etc.), solvents, process conditions (e.g., temperature, reaction time, etc.) and purification methods are already described herein above for the conversion of the compound of Formula III to give the compound of Formula IV can also be applied in this aspect for the O-methylation of the compound of Formula to give the compound of Formula IVa.
- The optional benzylamination reaction of the compound of Formula IVa, subsequent de-tritylation and N2-acetylation of the compound can afford lacosamide.
- In an embodiment of this aspect, racemization is avoided during the process of the present aspect.
- In an embodiment of this aspect, the lacosamide obtained by following the process of this aspect is substantially chirally pure. The substantial chiral purity refers to the purity in which no detectable amount of corresponding S-enantiomer is present in lacosamide.
- In another embodiment of this aspect, lacosamide prepared by following the process of this aspect is substantially free of impurities. Lacosamide having at least about 99% purity, preferably at least about 99.8% purity and most preferably at least about 99.9% purity can be obtained by the process of present aspect.
- In a fourth aspect, a process for the preparation of lacosamide is provided comprising the steps of:
-
- a) O-methylating the compound of Formula VII
-
-
- to produce a compound of Formula VIII;
-
-
- b) benzylaminating the compound of Formula VIII to produce a compound of Formula Va;
-
- c) de-tritylating the compound of Formula Va to produce a compound of Formula VIa; and
-
- d) acetylating the compound of Formula VIa to produce a compound of Formula Ia.
- The O-methylation, benzylamination, de-tritylation, acetylation steps (with respect to method, reaction agents, solvents, catalyst, bases, etc.) and process conditions (e.g., temperature, reaction time, etc.) are described herein for the preparation of 2-acetamido-N-benzyl-3-methoxypropionamide of Formula I can also be applied in this aspect, but for the preparation of lacosamide comprising the steps of this aspect.
- In an embodiment of this aspect, racemization is avoided during the process of the present aspect.
- In another embodiment of this aspect, the lacosamide obtained by following the process of this aspect is substantially chirally pure. The substantial chiral purity refers to the purity in which no detectable amount of corresponding S-enantiomer is present in lacosamide.
- In another embodiment of this aspect, lacosamide prepared by following the process of this aspect is substantially free of impurities. Lacosamide having at least about 99% purity, preferably at least about 99.8% purity and most preferably at least about 99.9% purity can be obtained by the process of present aspect.
- In a fifth aspect, a process for the preparation of lacosamide is provided comprising the steps of:
-
- a) benzylaminating the compound of Formula VII
-
-
- to produce a compound of Formula IX;
-
-
- b) O-methylating the compound of Formula IX to produce a compound of Formula Va;
-
- c) de-tritylating the compound of Formula Va to produce a compound of Formula VIa; and
-
- d) acetylating the compound of Formula VIa to produce a compound of Formula Ia.
- The O-methylation, benzylamination, de-tritylation, acetylation steps (with respect to method, reaction agents, solvents, catalyst, bases, etc.) and process conditions (e.g., temperature, reaction time, etc.) are described herein for the preparation of 2-acetamido-N-benzyl-3-methoxypropionamide of Formula I can also be applied in this aspect, but for the preparation of lacosamide comprising the steps of this aspect.
- In an embodiment of this aspect, racemization is avoided during the process.
- In another embodiment of this aspect, the lacosamide obtained by following the process of this aspect is substantially chirally pure. The substantial chiral purity refers to the purity in which no detectable amount of corresponding S-enantiomer is present in lacosamide.
- In another embodiment of this aspect, lacosamide prepared by following the process of this aspect is substantially free of impurities. Lacosamide having at least about 99% purity, preferably at least about 99.8% purity and most preferably at least about 99.9% purity can be obtained by the process of present aspect.
- In a sixth aspect, substantially chirally pure lacosamide is provided.
- In an embodiment of this aspect, lacosamide having chiral purity of more than about 99.8% is preferred. More preferably, lacosamide having chiral purity of at least about 99.9% and most preferably lacosamide having no detectable amount of corresponding S-enantiomer (i.e., 100% chiral purity) is an object of this aspect.
- In a seventh aspect, a composition comprising a pharmaceutically effective amount of substantially chirally pure lacosamide along with pharmaceutically acceptable carrier, diluent and/or excipient is provided.
- While the present invention has been described in terms of its specific aspects, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
- In the following section, aspects are described by way of examples to illustrate the processes of the invention. However, these do not limit the scope of the present invention. Several variants of these examples would be evident to persons ordinarily skilled in the art.
-
- To dichloromethane (500 ml), D-serine (50 g) was added at ambient temperature under nitrogen atmosphere to form a suspension and then trimethylsilyl chloride (180.91 g) was added to the suspension in 10-15 minutes at ambient temperature. The reaction mixture was refluxed at 35° C. to 40° C. for 20 minutes and then it was cooled to ambient temperature. To the reaction mixture, a solution of triethyl amine (168.50 g) dichloromethane (50 ml) was added in 30-45 minutes at 25° C. to 30° C. The mixture was refluxed for 45 minutes at 35° C. to 40° C. and then cooled to 0° C. To this mixture, a solution of anhydrous methanol (22.83 g) dichloromethane (50 ml) was added at 0° C. and the mixture was allowed to reach at room temperature. Triethylamine (48.14 g) was slowly added to it at 25° C. to 30° C. and then trityl chloride (132.63 g) was added in 3 lots to the mixture at an interval of 10 minutes. The reaction mixture was then stirred for 3 hours under nitrogen at ambient temperature. After completion of the reaction, methanol (76.12 g) was added at ambient temperature in 10-15 minutes and the solvent was recovered under vacuum at 40° C. to 45° C. The crude product obtained was washed with water (750 ml) and filtered. The filtered product was further washed with 5% citric acid solution (750 ml) and filtered. The solid product obtained was partitioned between water (750 ml) and hexanes (200 ml) and then filtered. The filtered solid was washed with hexanes (200 ml) and dried to obtain the titled product. Yield=135 gm.
- To dichloromethane (400 ml), D-serine (50 g) was added at ambient temperature under nitrogen atmosphere to form a suspension and then trimethylsilyl chloride (61.92 g) and hexamethyldisilazane (107.5 ml) were added to the suspension in 10-15 minutes at ambient temperature. The reaction mixture was refluxed at 35° C. to 40° C. for 3 hours and then it was cooled to 0° C. To this mixture, a solution of anhydrous methanol (22.83 g) in dichloromethane (50 ml) was added at 0° C. and the mixture was allowed to reach at room temperature. Triethylamine (48.14 g) was slowly added to it at 25° C. to 30° C. and then trityl chloride (132.63 g) was added in 3 lots to the mixture at an interval of 10 minutes. The reaction mixture was then stirred for overnight under nitrogen at ambient temperature. After completion of the reaction, methanol (76.12 g) was added at ambient temperature in 10-15 minutes and the solvent was recovered under vacuum at 40° C. to 45° C. Hexane (400 ml) and 5% citric acid solution (750 ml) was added to the recovered solid and filtered. The solid product obtained was washed with water (750 ml) and hexanes (200 ml) and then filtered. The filtered solid was washed with hexanes (200 ml) and dried to obtain the titled product. Yield=125 gm.
- To dichloromethane (400 ml), D-serine (50 g) was added at ambient temperature under nitrogen atmosphere to form a suspension and then hexamethyldisilazane (134.15 ml) was added to the suspension in 10-15 minutes at ambient temperature. Catalytic amount of ammonium chloride (1 gm) was added. The reaction mixture was refluxed at 35° C. to 40° C. for 3 hours and then it was cooled to 0° C. To this mixture, a solution of anhydrous methanol (22.83 g) dichloromethane (50 ml) was added at 0° C. and the mixture was allowed to reach at room temperature. Triethylamine (48.14 g) was slowly added to it at 25° C. to 30° C. and then trityl chloride (132.63 g) was added in 3 lots to the mixture at an interval of 10 minutes. The reaction mixture was then stirred for overnight under nitrogen at ambient temperature. After completion of the reaction, methanol (76.12 g) was added at ambient temperature in 10-15 minutes and the solvent was recovered under vacuum at 40° C. to 45° C. Toluene (400 ml) and 5% citric acid solution (750 ml) was added to the recovered solid and filtered. The solid product obtained was washed with water (750 ml) and hexanes (200 ml) and then filtered. The filtered solid was washed with toluene (200 ml) and dried to obtain the titled product. Yield=100 gm; Mass: (−EI): 346 (M−1); 242.9 (−Tr).
-
- To a mixture of sodium hydride (20.14 g), imidazole (1.959 g) and tetrahydrofuran (150 ml), a solution of Example 1 product (i.e., N-trityl-D-serine, 50 g) tetrahydrofuran (500 ml) was added and the mixture was stirred for 45 minutes at −15° C. Methyl iodide (40.8 g) was added to the mixture in 15 minutes at −15° C. to −5° C. and the reaction mixture was stirred at −5° C. for 3 hours. The temperature was raised to 0° C., water was added to it and then the tetrahydrofuran was recovered completely under vacuum at 40° C. Hexane (250 ml) was added to it and stirred for 15 minutes. The layers were separated and the aqueous layer was neutralized with acetic acid till pH=6.0. Dichloromethane (2×150 ml) was added to the aqueous layer and extracted. Organic layer was separated and solvent recovered under vacuum at 35° C. to 40° C. to obtain an oily residue. Hexane (100 ml) was added to the oily residue and the solution was stirred for 15 minutes. The product formed was isolated and dried to obtain compound of Formula VIII. Yield=40 gm.
- [α]D 23=+13.9 (c=1, EtOH)
- 1H NMR (CDCl3) δ: 7.42-7.25, (m, 15 Ph); 6.48 (Br s, NH, OH); 3.4-3.5 (m, CH 2—OCH3); 3.1 (s, OCH3) 2.36-2.41 (m CH—NH)
- Mass: 369.9 (M−1);
- IR (KBr): 3300, 3294, 2927, 2826, 1655, 1527, 1455, 1360, 1251, 1181, 1106, 971, 734 cm−1
-
- To a solution of Example 2 product (i.e., O-methyl-N-trityl-D-serine, 50 g) in tetrahydrofuran (500 ml), N-methyl morpholine (20.9 g) was added at −15° C. in 5-10 minutes. The reaction mixture was stirred for 15 minutes and then isobutylchloroformate (18.8 g) diluted with tetrahydrofuran was added to it at 15° C. under nitrogen atmosphere in 15-20 minutes. The solution was stirred for 15 minutes and benzyl amine (14.7 g) was added to it at −0.15° C. in 15 minutes. The solution was allowed to cool to room temperature and stirred for 2 hours. The solvent was recovered from the solution. Dichloromethane (250 ml) was added to the crude product and stirred for 5 minutes to dissolve. The dichloromethane layer was washed or stirred for 5 minutes with water (250 ml). The layers were separated and the dichloromethane layer was again washed with 5% NaHCO3 (250 ml). The layers were separated and then the dichloromethane layer was sequentially washed with 5% citric acid solution (250 ml) and then with water (250 ml). The solvent was recovered at 40° C. to 45° C. to get oil. Ethyl acetate was added to the oil and the mixture was heated to 60° C. to 65° C. to dissolve. The clear solution so formed was cooled up to room temperature and then hexanes (350 ml) were added to it. It was stirred for 1 hour at room temperature, filtered and then dried to get compound of Formula Va. Yield=30 gm.
- To a solution of Example 2 product (i.e., O-methyl-N-trityl-D-serine, 50 g) in ethyl acetate (500 ml), N-methyl morpholine (20.9 g) was added at −15° C. in 5-10 minutes. The reaction mixture was stirred for 15 minutes and then isobutylchloroformate (18.8 g) already diluted with tetrahydrofuran was added to it at −15° C. under nitrogen atmosphere in 15-20 minutes. The solution was stirred for 15 minutes and benzyl amine (14.7 g) was added to it at −15° C. in 15 minutes. The solution was allowed to cool to room temperature and stirred for 2 hours. The solvent was recovered from the solution. Dichloromethane (250 ml) was added to the crude product and stirred for 5 minutes to dissolve. The dichloromethane layer was washed or stirred for 5 minutes with water (250 ml). The layers were separated and the dichloromethane layer was again washed with 5% NaHCO3 (250 ml). The layers were separated and then the dichloromethane layer was sequentially washed with 5% citric acid solution (250 ml) and then with water (250 ml). The solvent was recovered at 40° C. to 45° C. to get oil. Ethyl acetate was added to the oil and the mixture was heated to 60° C. to 65° C. to dissolve. The clear solution so formed was cooled up to room temperature and then hexanes (350 ml) were added to it. It was stirred for 1 hour at room temperature, filtered and then dried to get compound of Formula Va. Yield=31 gm.
- Spectroscopic Data of N-benzyl-O-methyl-N2-trityl-D-serinamide
- [α]D 23=−91.7 (c=1, EtOH)
- 1H NMR: 78 (m, NH) 7.41-7.43 (m, 5 Ph); 7.16-7.36 (m, 15 Ph); 4.3-4.5 (m, CH2—NH); 3.49-3.50 (CHH—OCH3) 3.46-3.47 (m, CHH—OCH3); 3.06 (s, OCH3) 2.01-2.06 (m, CH—NH); IR (KBr): 3294, 3024, 2829, 1622, 1527, 1428, 1370 cm−1; Mass: 451 (M+1); 243.3 (Tr).
-
- To a solution of Example 3 product (i.e. N-benzyl-O-methyl-N2-trityl-D-serinamide, 50 g) in dichloromethane (100 ml), hydrochloric acid (36%) was added at room temperature. This solution was stirred for 30 minutes at room temperature and then the solvent was completely recovered under vacuum at 40° C. Water (250 ml) was added to it at room temperature and the aqueous layer was neutralized with aqueous ammonia (20 ml). The aqueous layer was extracted with toluene (2×200 ml). The toluene was then completely recovered under vacuum at 50° C. to 55° C. to get an oil. Yield=15 gm.
- To a solution of Example 3 product (i.e., N-benzyl-O-methyl-N2-trityl-D-serinamide, 50 g) in absolute ethanol (100 ml), acetic acid (1.25 mole eq.) was added at room temperature. This solution was stirred for 30 minutes at room temperature and then the solvent was completely recovered under vacuum at 40° C. Water (250 ml) was added to it at room temperature and the aqueous layer was neutralized with aqueous ammonia (20 ml). The aqueous layer was extracted with toluene (2×200 ml). The toluene was then completely recovered under vacuum at 50° C. to 55° C. to get an oil. Yield=18 gm.
- IR (liq. film); 3352, 3311, 3064, 2964, 2927, 2826, 1655, 1527, 1455, 1360, 1251, 1181, 1106, 971, 734, 700 cm−1; 1H NMR (CDCl3) δ: 1.85 (br, s, NH2); 3.34 (s, OCH3) 3.56-3.62 (m, CHOCH2), 4.39 (dd, NHCHH), 4.45 (dd, NHCHH); 7.20-7.36 (m, 5 PhH) 7.80-7.88 (m, NH); MS (+CI): 209 (M++1).
-
- N-trityl-D-serine (50 g), prepared by following Example 1, was mixed with tetrahydrofuran (500 ml) and the solution was cooled to −15° C. N-methyl morpholine (15.72 g) was added to it at −15° C. in 5-10 minutes. The solution was stirred for 15 minutes and isobutylchloroformate (20.84 g) diluted with tetrahydrofuran was added to it in 15-20 minutes at −15° C. under nitrogen atmosphere. The solution was stirred for 15 minutes and benzyl amine (18.51 g) was added to it in 15 minutes at −15° C. The solution was further stirred for 45 minutes at −15° C. The solution was allowed to cool to room temperature and stirred for 2 hours. The solvent was recovered from the solution. Dichloromethane (250 ml) was added to the crude product and stirred for 5 minutes to dissolve. The dichloromethane layer was washed or stirred for 5 minutes with water (250 ml). The layers were separated and the dichloromethane layer was again washed with 5% NaHCO3 (250 ml). The layers were separated and then the dichloromethane layer was sequentially washed with 5% citric acid solution (250 ml) and then with water (250 ml). The solvent was recovered at 40° C. to 45° C. to get oil. Ethyl acetate (150 ml) was added to the oil and the mixture was heated to 60° to 65° C. to dissolve. The clear solution so formed was cooled up to room temperature and then hexanes (350 ml) were added to it. It was stirred for 1 hour at room temperature, filtered and then dried to get the compound of Formula IX. Yield=45 gm.
- N-trityl-D-serine (50 g), prepared by following Example 1, was mixed with ethyl acetate (500 ml) and the solution was cooled to −15° C. N-methyl morpholine (15.72 g) was added to it at −15° C. in 5-10 minutes. The solution was stirred for 15 minutes and isobutylchloroformate (20.84 g) diluted with tetrahydrofuran was added to it in 15-20 minutes at −15° C. under nitrogen atmosphere. The solution was stirred for 15 minutes and benzyl amine (18.51 g) was added to it in 15 minutes at −15° C. The solution was further stirred for 45 minutes at −15° C. The solution was allowed to cool to room temperature and stirred for 2 hours. The solvent was recovered from the solution. Dichloromethane (250 ml) was added to the crude product and stirred for 5 minutes to dissolve. The dichloromethane layer was washed or stirred for 5 minutes with water (250 ml). The layers were separated and the dichloromethane layer was again washed with 5% NaHCO3 (250 ml). The layers were separated and then the dichloromethane layer was sequentially washed with 5% citric acid solution (250 ml) and then with water (250 ml). The solvent was recovered at 40° C. to 45° C. to get oil. Ethyl acetate (150 ml) was added to the oil and the mixture was heated to 60° C. to 65° C. to dissolve. The clear solution so formed was cooled up to room temperature and then hexanes (350 ml) were added to it. It was stirred for 1 hour at room temperature, filtered and then dried to get the compound of Formula IX. Yield=45.5 gm.
-
- To a mixture of sodium hydride (6.59 g), imidazole (1.564 g) and tetrahydrofuran (150 ml), a solution of Example 5 product (i.e. N-benzyl-N2-trityl-D-serinamide, 50 g) in tetrahydrofuran (500 ml) was slowly added at −15° C. and the mixture was stirred for 45 minutes at −15° C. Methyl iodide (24.38 g) was slowly added to the mixture for 15 minutes at −15° C. to −5° C. and the formed reaction mixture was stirred at −5° C. for 3 hours. The reaction mixture was cooled to 0° C. water was added to it and then the tetrahydrofuran was recovered completely under vacuum at 40° C. Hexane (250 ml) was added to it and stirred for 15 minutes. The layers were separated and the aqueous layer was neutralized with acetic acid till pH=6.0. Dichloromethane (2×150 ml) was added to the aqueous layer and layers were separated. Oily product was recovered under vacuum at 35° C. to 40° C. from the organic layer. Hexane (100 ml) was added to the oily product and the solution formed was stirred for 15 minutes, filtered and dried to get the titled product of Formula Va.
- Yield=30 gm.
- To a mixture of DMSO (8 g) and pulverized KOH (0.308 g), Example 5 product (i.e., N-benzyl-N2-trityl-D-serinamide, 2 g) was added in one lot. It was stirred for 3 hours at ambient temperature. Methyl iodide (0.97 g) was slowly added to the mixture for 15 minutes at ambient temperature and stirred for 30 minutes. The reaction mixture was cooled to 0° C., water was added to it and the product was isolated with toluene. Oily product was recovered under vacuum at 35° C. to 40° C. from the organic layer. Hexane (100 ml) was added to the oily product and the solution formed was stirred for 15 minutes, filtered and dried to get the titled product of Formula Va. Yield=1 gm.
- Spectroscopic Data of N-benzyl-O-methyl-N2-trityl-D-serinamide
- [α]D 23=91.7 (c=1, EtOH)
- 1H NMR: 78 (m, NH) 7.41-7.43 (m, 5 Ph); 7.16-7.36 (m, 15 Ph); 4.3-4.5 (m, CH2—NH); 3.49-3.50 (CHH—OCH3) 3.46-3.47 (m, CHH—OCH3); 3.06 (s, OCH3) 2.01-2.06 (m, CH—NH); IR (KBr): 3294, 3024, 2829, 1622, 1527, 1428, 1370 cm−1; Mass: 451 (M+1); 243.3 (Tr).
-
- N-benzyl-O-methyl-D-serinamide (50 g), prepared by sequentially following Example 1 to Example 4, was mixed with dichloromethane (500 ml) at ambient temperature and stirred to get clear solution. To this solution, dimethylaminopyridine (1.04 g) was added at ambient temperature. The solution was cooled to 10° to 5° C. and then acetic anhydride (24.48 g) was slowly added to it for 10-15 minutes at 10° to 5° C. The solution was stirred for 10 minutes at 10° to 5° C. and raised to room temperature (25°-30° C.) in over 30 minutes. The solution was further stirred for 30 minutes at room temperature. The reaction mixture was washed with 8% sodium bicarbonate (250 ml) solution. It was again washed with water (250 ml). The layers were separated and solvent was completely recovered under vacuum at 40° C. to 48° C. to get a solid product. Yield 50 gm; mp: 142° C.-143° C. Chiral purity of lacosamide by HPLC, 99.98%.
- N-benzyl-O-methyl-D-serinamide (50 g), prepared by sequentially following Example 1 to Example 4, was mixed with ethyl acetate (500 ml) at ambient temperature and stirred to get clear solution. To this solution, dimethylaminopyridine (1.04 g) was added at ambient temperature. The solution was cooled to 10° to 5° C. and then acetic anhydride (24.48 g) was slowly added to it for 10-15 minutes at 10° to 5° C. The solution was stirred for 10 minutes at 10° to 5° C. and raised to room temperature (25° to 30° C.) in over 30 minutes. The solution was further stirred for 30 minutes at room temperature. The reaction mixture was washed with 8% sodium bicarbonate (250 ml) solution. It was again washed with water (250 ml). The layers were separated and solvent was completely recovered under vacuum at 40° C. to 48° C. to get a solid product. Yield=49.5 gm; mp: 142° C.-143° C. Chiral purity of lacosamide by HPLC, 99.98%.
-
- N-benzyl-O-methyl-D-serinamide (50 g), prepared by sequentially following Example 1, 5, 6 and 4, was mixed with dichloromethane (500 ml) at ambient temperature and stirred to get clear solution. To this solution, dimethylaminopyridine (1.04 g) was added at ambient temperature. The solution was cooled to 10° to 5° C. and then acetic anhydride (24.48 g) was slowly added to it for 10-15 minutes at 10° to 5° C. The solution was stirred for 10 minutes at 10° to 5° C. and raised to room temperature (25°-30° C.) in over 30 minutes. The solution was further stirred for 30 minutes at room temperature. The reaction mixture was washed with 8% sodium bicarbonate (250 ml) solution. It was again washed with water (250 ml). The layers were separated and solvent was completely recovered under vacuum at 40° C. to 48° C. to get solid product. Yield=49 gm; mp: 142° C.-143° C. Chiral purity of lacosamide by HPLC, 99.98%.
- N-benzyl-O-methyl-D-serinamide (50 g), prepared by sequentially following Example 1, 5, 6 and 4, was mixed with ethyl acetate (500 ml) at ambient temperature and stirred to get clear solution. To this solution, dimethylaminopyridine (1.04 g) was added at ambient temperature. The solution was cooled to 10° to 5° C. and then acetic anhydride (24.48 g) was slowly added to it for 10-15 minutes at 10° to 5° C. The solution was stirred for 10 minutes at 10° to 5° C. and raised to room temperature (25° to 30° C.) in over 30 minutes. The solution was further stirred for 30 minutes at room temperature. The reaction mixture was washed with 8% sodium bicarbonate (250 ml) solution. It was again washed with water (250 ml). The layers were separated and solvent was completely recovered under vacuum at 40° C. to 48° C. to get solid product. Yield=49.5 gm; mp: 142° C.-143° C. Chiral purity of lacosamide by HPLC, 99.98%.
- N-benzyl-O-methyl-D-serinamide (92 g), was mixed with dichloromethane (368 ml) at ambient temperature and stirred for 10 minutes to get a clear solution. To this solution, dimethylaminopyridine (0.47 g) was added at ambient temperature. Acetic anhydride (45.09 g) was slowly added over 15-20 minutes at ambient temperature. The solution was stirred for 2 hours at room temperature. The reaction mixture was washed with sodium hydroxide (19.16 gm dissolved in 291 ml water), and deionized water (276 ml). The layers were separated and solvent was completely recovered under vacuum at 35° C. to 40° C. to get crude product. Yield=82.6 gm; Chiral purity=100%.
- 5 gm of the crude product was dissolved in toluene (35 ml) and heated to 80° C. It was then cooled to room temperature and stirred for 30 minutes. The material was cooled further to 0° C. and stirred for 30 minutes at the same temperature. The mixture was filtered, and washed with chilled toluene (2×10 ml). The filtrate was suck-dried for 15 minutes and dried under vacuum at 45° C. to 50° C. Dried wt==4.5 gm; Chiral purity of lacosamide by HPLC, 100.00%,
- N-benzyl-O-methyl-D-serinamide (5 g), was mixed with DCM (25 ml) at ambient temperature and stirred for 10 minutes to get a clear solution. To this solution, dimethylaminopyridine (0.025 g) was added at ambient temperature. Acetic anhydride (2.695 g) was slowly added over 10-12 minutes at ambient temperature. The solution was stirred for 30 minutes at room temperature. The reaction mixture was washed with 5% sodium bicarbonate (15 ml) solution, deionized water (15 ml), and brine (10 ml). The layers were separated and solvent was completely recovered under vacuum at 35° C. to 40° C. to get crude product. Yield=5.9 gm.
- 1 gm of the crude product was dissolved in ethyl acetate (6 ml) and heated to reflux to get a clear solution. The mixture was cooled to room temperature in 1 hour, cooled further to 5° C. in 15 minutes, then stirred for 1 hour at 5° C. to 10° C. The solid was filtered, and washed with chilled ethyl acetate (3.0 ml). The material was suck-dried for 15 minutes, and finally dried under vacuum at 50° C. to 55° C. Dried wt=0.5 g. Chiral purity of lacosamide by HPLC, 100.00%.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/154,807 US20120004452A1 (en) | 2007-12-04 | 2011-06-07 | Intermediate compounds and their use in preparation of lacosamide |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2542DE2007 | 2007-12-04 | ||
| IN2542/DEL/2007 | 2007-12-04 | ||
| US12/327,124 US8093426B2 (en) | 2007-12-04 | 2008-12-03 | Intermediate compounds and their use in preparation of lacosamide |
| US13/154,807 US20120004452A1 (en) | 2007-12-04 | 2011-06-07 | Intermediate compounds and their use in preparation of lacosamide |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/327,124 Division US8093426B2 (en) | 2007-12-04 | 2008-12-03 | Intermediate compounds and their use in preparation of lacosamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20120004452A1 true US20120004452A1 (en) | 2012-01-05 |
Family
ID=40377199
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/327,124 Expired - Fee Related US8093426B2 (en) | 2007-12-04 | 2008-12-03 | Intermediate compounds and their use in preparation of lacosamide |
| US13/154,769 Expired - Fee Related US8378142B2 (en) | 2007-12-04 | 2011-06-07 | Intermediate compounds and their use in preparation of lacosamide |
| US13/154,807 Abandoned US20120004452A1 (en) | 2007-12-04 | 2011-06-07 | Intermediate compounds and their use in preparation of lacosamide |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/327,124 Expired - Fee Related US8093426B2 (en) | 2007-12-04 | 2008-12-03 | Intermediate compounds and their use in preparation of lacosamide |
| US13/154,769 Expired - Fee Related US8378142B2 (en) | 2007-12-04 | 2011-06-07 | Intermediate compounds and their use in preparation of lacosamide |
Country Status (2)
| Country | Link |
|---|---|
| US (3) | US8093426B2 (en) |
| EP (1) | EP2067765A3 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100240926A1 (en) * | 2009-03-18 | 2010-09-23 | Pliva Hrvatska D.O.O. | Process for preparing (r)-n-benzyl-2-(benyloxycarbonylamino)-3-methoxypropionamide |
| CN102596897A (en) | 2009-08-06 | 2012-07-18 | 麦迪凯姆股份公司 | Solid forms of an N-(phenylmethyl)propanamide derivative and processes of preparation |
| WO2011039781A1 (en) * | 2009-09-25 | 2011-04-07 | Cadila Healthcare Limited | Processes for the preparation of lacosamide and intermediates thereof |
| US20130085304A1 (en) | 2009-11-19 | 2013-04-04 | Ranbaxy Laboratories Limited | Processes for preparation of polymorphic forms of lacosamide |
| IT1398044B1 (en) * | 2010-01-29 | 2013-02-07 | Archimica Srl | PROCESS FOR THE PREPARATION OF LACOSAMIDE |
| US8853453B2 (en) | 2010-01-29 | 2014-10-07 | Ranbaxy Laboratories Limited | Processes for reducing impurities in lacosamide |
| WO2011095995A1 (en) | 2010-02-08 | 2011-08-11 | Natco Pharma Limited | A process for the preparation of lacosamide |
| US8907132B2 (en) | 2010-02-09 | 2014-12-09 | Msn Laboratories Private Limited | Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide |
| WO2011130615A2 (en) * | 2010-04-15 | 2011-10-20 | Dr. Reddy's Laboratories Ltd. | Preparation of lacosamide |
| WO2011144983A2 (en) | 2010-05-17 | 2011-11-24 | Aurobindo Pharma Limited | An improved process for the preparation of lacosamide |
| US20130095535A1 (en) | 2010-06-15 | 2013-04-18 | Medichem, S.A. | Enzymatic resolution of racemic (2r,s)-2-(acetylamino)-3-methoxy-n-(phenylmethyl)propanamide |
| EP2399901A1 (en) | 2010-06-23 | 2011-12-28 | Archimica GmbH | Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide |
| WO2012001710A1 (en) * | 2010-07-02 | 2012-01-05 | Sun Pharmaceutical Industries Ltd | An improved process for the preparation of lacosamide |
| WO2012014226A1 (en) | 2010-07-27 | 2012-02-02 | Indoco Remedies Limited | Process for preparation of lacosamide and some n-benzyl-propanamide intermediate derivatives |
| CN101891885B (en) * | 2010-08-18 | 2012-12-12 | 中国科学院长春应用化学研究所 | Poly-serine ester and preparation method thereof |
| PL2444390T3 (en) | 2010-10-19 | 2017-06-30 | Euticals Gmbh | Process for producing Lacosamide |
| GB201020026D0 (en) | 2010-11-25 | 2011-01-12 | Cambrex Karlskoga Ab | New process |
| MX337610B (en) * | 2011-08-29 | 2016-03-10 | Signa S A De C V | Processes for the preparation of (r)-2-acetamido-n-benzyl- 3-methoxypropionamide and intermediates thereof. |
| US9199916B2 (en) | 2011-11-10 | 2015-12-01 | Ramamohan Rao Davuluri | Process for the preparation of (R)-N-benzyl-2-acetamido-3-methoxypropionamide |
| CN103930397B (en) * | 2011-11-15 | 2015-10-21 | 塞诺菲-安万特德国有限公司 | Process for the production of N-substituted 2-(acetylamino)-N'-benzyl-3-methoxypropionamides |
| US8748660B2 (en) | 2012-07-09 | 2014-06-10 | Council Of Scientific & Industrial Research | Process for the synthesis of antiepileptic drug lacosamide |
| CN102816083B (en) * | 2012-07-30 | 2015-09-23 | 永光制药有限公司 | The preparation method of scheme for lacosamide |
| GB201219627D0 (en) | 2012-11-01 | 2012-12-12 | Cambrex Karlskoga Ab | New process |
| WO2014155264A1 (en) | 2013-03-25 | 2014-10-02 | Jubilant Life Sciences Limited | Process for the preparation of lacosamide using novel intermediates |
| CA2958283A1 (en) * | 2014-08-28 | 2016-03-03 | RAO, Davuluri Ramamohan | Improved process for the preparation of lacosamide and its novel intermediate |
| JPWO2016039393A1 (en) * | 2014-09-10 | 2017-06-22 | 株式会社エーピーアイ コーポレーション | Method for producing amino acid derivative |
| WO2016125178A1 (en) * | 2015-02-04 | 2016-08-11 | Satyendra Kumar Pandey | Improved process for the preparation of (r)-lacosamide |
| IN2015CH05001A (en) | 2015-09-18 | 2015-10-16 | Divis Lab Ltd | |
| US10975117B2 (en) | 2015-11-13 | 2021-04-13 | Api Corporation | Method for producing lacosamide and intermediate thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05125029A (en) | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | New amide compound or its salt |
| US5773475A (en) | 1997-03-17 | 1998-06-30 | Research Corporation Technologies, Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| ES2218024T3 (en) * | 1996-03-15 | 2004-11-16 | Research Corporation Technologies, Inc | ANTI-CONVULSIONING ENANTIOMERIC AMINO ACID DERIVATIVES. |
| US6048899A (en) | 1997-03-17 | 2000-04-11 | Research Corporation Tech., Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| EP1642889A1 (en) | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
-
2008
- 2008-12-03 US US12/327,124 patent/US8093426B2/en not_active Expired - Fee Related
- 2008-12-04 EP EP08170733A patent/EP2067765A3/en not_active Withdrawn
-
2011
- 2011-06-07 US US13/154,769 patent/US8378142B2/en not_active Expired - Fee Related
- 2011-06-07 US US13/154,807 patent/US20120004452A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120004462A1 (en) | 2012-01-05 |
| US8093426B2 (en) | 2012-01-10 |
| EP2067765A3 (en) | 2010-09-08 |
| US8378142B2 (en) | 2013-02-19 |
| EP2067765A2 (en) | 2009-06-10 |
| US20090143472A1 (en) | 2009-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8378142B2 (en) | Intermediate compounds and their use in preparation of lacosamide | |
| KR100572687B1 (en) | Method for preparing optically pure 4-hydroxy-2-oxo-1-pyrrolidineacetamide | |
| US7462738B2 (en) | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof | |
| KR101036536B1 (en) | Synthesis of (S)-(+)-3- (aminomethyl) -5-methyl hexanoic acid | |
| KR20120128667A (en) | A process for the preparation of lacosamide | |
| WO2008078482A1 (en) | Process for producing intermediate of asenapine synthesis | |
| US8853453B2 (en) | Processes for reducing impurities in lacosamide | |
| WO1998030538A1 (en) | Process for producing cysteine derivatives | |
| US12077484B2 (en) | Process for the synthesis of melphalan | |
| JP4522263B2 (en) | Method for producing benzylamine derivative | |
| US8143448B2 (en) | Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives | |
| US20110319649A1 (en) | Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide | |
| HK1133250A (en) | Intermediate compounds and their use in preparation of lacosamide | |
| EP3110791B1 (en) | Process for preparing 2,4-diamino-3-hydroxybutyric acid derivatives | |
| US7473803B2 (en) | Process for production of optically active 2-halogeno-carboxylic acids | |
| US8680298B2 (en) | Process for the preparation of orlistat | |
| US20170298093A1 (en) | Process for the Preparation of (S)-4-Methyl-N-((S)-1-(((S)-4-Methyl-1-((R)-2-Methyloxiran-2-YL)-1-OXO Pentan-2-YL) Amino)-1-OXO-3-Phenylpropan-2-YL)-2-((S)-2-(2-Morpholinoacetamido)-4-Phenylbutanamido) Pentanamide | |
| CN104364229B (en) | Synthesis of diamide-based gelling agents by using Deng's salts of amino acids | |
| JP2005041854A (en) | Optically active N- (2-substituted-3-halopropionyl) amino acids and method for producing the same, and method for producing optically active N- (2-substituted-3-acylthiopropionyl) amino acids using the same | |
| US10723691B2 (en) | Process for preparing salicyloyl-L-carnitine hydrochloride | |
| WO2007099894A1 (en) | General-purpose deprotecting method using sulfur oxide | |
| JP2002255932A (en) | Method for producing 3-alkylaminoazetidine | |
| JP2005298337A (en) | Process for producing β-hydroxyamino acid derivative and its intermediate | |
| JP2006016314A (en) | Method for producing optically active amide compound | |
| JPH09278734A (en) | Production of optically active cyanohydrin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: RANBAXY LABORATORIES LIMITED, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MADHRA, MUKESH KUMAR;SINGH, PANKAJ KUMAR;KHANDURI, CHANDRA HAS;REEL/FRAME:026402/0369 Effective date: 20081210 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |